CD68 and neoplasm: The percentages of VISTA and PD-L1 expression on tumor-infiltrating CD4+ and CD8+ T cells and CD68+ macrophages were significantly increased after therapy, suggesting that both checkpoint proteins may contribute to the immunosuppressive tumor microenvironment (TME) and resistance to negative immune checkpoint blockade therapy (8).